A novel demographic-based model shows that intensive testing and social distancing are concurrently required to extinguish COVID-19 progression in densely populated urban areas

Mario Moisés Alvarez[1,2,*] and Grissel Trujillo-de Santiago[1,3]

[1] Centro de Biotecnología-FEMSA, Tecnologico de Monterrey, Monterrey 64849, NL, México

[2] Departamento de Bioingeniería, Escuela de Ingeniería y Ciencias, Tecnologico de Monterrey, Monterrey 64849, NL, México

[3] Departamento de Ingeniería Mecatrónica y Eléctrica, Escuela de Ingeniería y Ciencias, Tecnologico de Monterrey, Monterrey 64849, NL, México

(*) corresponding author: *mario.alvarez@tec.mx*

Abstract

We present a simple epidemiological model that includes demographic density, social distancing, and efficacy of massive testing and quarantine as the main parameters to model the progression of COVID-19 pandemics in densely populated urban areas (i.e., above 5,000 inhabitants km^2). Our model demonstrates that effective containment of pandemic progression in densely populated cities is achieved only by combining social distancing and widespread testing for quarantining of infected subjects. Our results suggest that extreme social distancing without intensive testing is ineffective in extinguishing COVID-19. This finding has profound epidemiological significance and sheds light on the controversy regarding the relative effectiveness of widespread testing and social distancing. Our simple

epidemiological simulator is also useful for assessing the efficacy of governmental/societal

responses to an outbreak.

This study also has relevant implications for the concept of smart cities, as densely

populated areas are hotspots that are highly vulnerable to epidemic crises.

Keywords: *COVID-19, SARS-CoV2, mathematical modeling, social distancing, massive*

testing, pandemic, demographic

Submitted to *PLoS One*

36 Introduction

COVID-19 has clearly illustrated that we were unprepared for the second pandemic of the

21st century. By the third week of July 2020, the official cumulative number of infected

persons worldwide was more than 14,000,000, with a death toll higher than 600,000.

COVID-19 has not recognized frontiers; it started in China, migrated to Iran, and formed a

later epicenter in Italy and Spain. It then extended to France, England, Germany, and other

European Countries. Now, COVID-19 has a strong presence in Las Americas, the current

epicenter of the pandemics, mainly in the USA, Brazil, and Mexico[1,2]. India just became

the third country with the most officially confirmed cases (after USA and Brazil) currently

reports more than 1,000,000 cases of COVID-19. Precisely India, USA, Brazil and México

concentrate many of the most densely populated cities in the planet (i.e., New York,

Kalcota, Bangalore, Sao Paulo, Rio de Janeiro, and México City). Among all affected

territories, pandemic COVID-19 has encountered containment responses ranging from

aggressive to weak. Some of these responses, namely the ones that appear to be more

successful, have been based on a combination of social distancing and massive testing and

selective quarantine[3]. Social distancing effectively decreases the progression of the

disease essentially by decreasing the demographic density, while massive testing enables

the identification of infected subjects and opportune quarantining[4] (which is technically a

version of selective social distancing). However, discussion persists regarding the relative

effectiveness of countermeasures such as social distancing or massive testing, and countries

have used social distancing and testing effort with widely different emphasis to face

COVID-19. Countries like South Korea have based their strategy of containment on strict

social distancing and massive testing in their open populations[5]. Spain initially based its

strategy on gradual social distancing. Later, it significantly increased its diagnostic efforts

to plateau the pandemic. England started by using testing mainly for epidemiological

recording, but later significantly scaled up its efforts to aggressively diagnose its

population. By contrast, Mexican officials have openly declared that massive testing and

quarantine have no significant value as a countermeasure for COVID-19 progression and

that diagnostics is mostly informative; Mexico has been one of the countries with the

fewest diagnostic tests conducted per 100,000 inhabitants[6].

The benefit of social distancing and massive diagnostics has not only been a subject of

controversy[7], but assessing the potential benefit has also been challenging.

Here, we introduce a simple mathematical model with a formulation that explicitly

considers demographic variables (i.e., the demographic density and the total population) to

calculate the progression of COVID-19 in urban areas. The model also considers the

effectiveness of social distancing measures and of massive testing for expeditious

identification and quarantining of infective subjects as inputs. We present a wide range of

simulation scenarios for "representative" urban areas and show that both social distancing

and widespread and effective testing should be combined for effective containment of the

pandemic advance in densely populated urban areas.

Model formulation

We developed a very simple epidemiological model for the propagation of COVID-19 in

urban areas (Figure 1A; S1 File). The model considers two variable populations of

individuals, infected (X) and retrieved (R). The cumulative number of infected patients (X)

is the total number of subjects among the population that have been infected by SARS-

CoV-2. The number of retrieved patients should be interpreted as the number of individuals

that have been retrieved from the general population and are not contributing to the

propagation of COVID-19. Retrieved subjects include subjects who have recovered from

the infection and do not shed virus, quarantined individuals, and deceased patients.

Importantly, the model assumes that infection results in (at least) short-term immunity upon

recovery. This assumption is based in experimental evidence that suggests that rhesus

macaques that recovered from SARS-CoV-2 infection could not be reinfected[8]. However,

the acquisition of full immunity to reinfection has not been confirmed in humans, although

it is well documented for other coronavirus infections, such as SARS and MERS[9,10].

Two set of parameters, demographic and clinical/epidemiological, determine the interplay

between these two main populations and other subpopulations that include asymptomatic

infected (A), symptomatic infected (S), and deceased (D). Clinical parameters include an

intrinsic infection rate constant (μ_o) that is calculated from the initial stage of the pandemic

in that particular region, the fraction of asymptomatic patients (a), the delay between the

period of viral shedding by an infected patient (delay_r), the period from the onset of

shedding to the result of first diagnosis and quarantine in the fraction of patients effectively

diagnosed (delay_q), and the fraction of infected patients effectively diagnosed and

retrieved from the population (α). Demographic parameters include the population of the

region (P_o), the relative demographic density (δ), the social distancing (σ), and the fraction

of infected individuals retrieved from the population due to massive and effective testing

(α) (Figure 1A). The model is based on a set of two simple differential equations.

$$dX/dt = \mu_o \, \delta \, (1\text{-}\sigma) \, (X\text{-}R) \, (P_o\text{-}X)/P_o \qquad\qquad \text{equation (1)}$$

$$dR/dt = \alpha \int_{t=0}^{t=t-delay\_q} dX/dt - (1\text{-}\alpha) \int_{t=0}^{t=t-delay\_r} dX/dt \qquad \text{equation (2)}$$

The first equation of the set (equation 1) states that the rate of accumulation of infected

habitants (symptomatic and asymptomatic) in an urban area (assumed to be a closed

system) is proportional to the number of infective subjects (X-R) present in that population

at a given point and the fraction of the population susceptible to infection ((P_o-X)/P_o). Note

that the number of infective subjects is given by the difference between the accumulated

number of infected subjects (X) and the number of retrieved subjects (R). The fraction of

the susceptible population decreases over time as more inhabitants in the community get

infected. The proportionality constant in equation 1 (μ_o) is an intrinsic rate of infection that

is weighted by the population density (δ) in that urban area, and the effective fractional

reduction of social distancing on the population density (1- σ).

The second equation (equation 2) describes the rate at which infected patients are retrieved

from the infective population. Eventually, all infected subjects are retrieved from the

population of infected individuals, but this occurs at distinctive rates. A fraction of infected

individuals (α) is effectively retrieved from the general population soon after the onset of

symptoms or after a positive diagnosis. Another fraction of infected subjects (1- α) is not

effectively retrieved from the population until they have recovered or died from the disease.

Therefore, in our formulation, the overall rate of retrieval (dR/dt) has two distinctive

contributions, each one associated with different terms on the right-hand side of equation 2.

The first term accounts for the active rate of retrieving infected patients through the

diagnosis and quarantine of SARS-CoV-2 positive subjects. For this term, the delay from

the onset of virus shedding to positive diagnosis and quarantine (delay_q) is considered

short (*i.e.*, between two or three days), to account for a reasonable time between the

positive diagnosis and the action of quarantine. In our model formulation, this term is

represented by (1-α). A second term relates to the recovery or death of infected patients

(symptomatic or asymptomatic) and is represented by the integral of all infected subjects

recovered or deceased from the onset of the epidemic episode in the region, considering a

delay of 21 days (delay_r), which accounts for the average time of recovery of an infected

individual. Note that the simultaneous solution of equations 1 and 2 is sufficient to describe

the evolution of the number of asymptomatic individuals (A), symptomatic individuals (S),

and deceased patients (D) through the specification of several constants and simple

relations.

$$a \, dX/dt = dA/dt \qquad\qquad \text{equation (3)}$$

$$(1-a) \, dX/dt = dS/dt \qquad\qquad \text{equation (4)}$$

$$m \, [(1-a) \, dX/dt \,] = dD/dt \qquad\qquad \text{equation (5)}$$

Here, **a** is the fraction of asymptomatic subjects among the infected population, (1-**a**) is the

fraction of infected individuals that exhibit symptoms, and **m** is the mortality rate expressed

as a fraction of symptomatic individuals.

Selection of relevant epidemiological parameters

As with any epidemiological model, this model relies on some basic assumptions that must be sustained in clinical or epidemiological data (Table 1). We now briefly discuss the assumptions that were made and the rationale behind the relevant values of the parameters of the model: the fraction of asymptomatic infected, the average time to recover, the fraction of symptomatic patients that would require hospitalization, and the average time of bed occupancy per hospitalized patient.

The fraction of asymptomatic infected is one of the critical inputs to the model; it determines the final and maximum feasible threshold of symptomatic infected. However, the current evidence is not yet sufficient to support a conclusive value for this parameter. Nevertheless, a recent serological study conducted in New York City (NYC) found anti-SARS-CoV-2 IGGs among 21.2% of the population[11] (www.cnn.com), and this result is consistent with previous information related to massive epidemic episodes. For instance, in the context of the pandemic influenza A/H1N1/2009, up to 20–40% of the population in urban areas (i.e., Monterrey, México, and Pittsburgh, USA) [12,13] exhibited specific antibodies regardless of experiencing symptoms, while the fraction of confirmed symptomatic infections was lower than less than 10%. This serological result based exclusively on information from NYC suggests that more than 90% of exposed New Yorkers (~91.4%) were asymptomatic or exhibited minor symptoms. Based on this (still unpublished) data, we assumed a symptomatic fraction of only 10% in the calculations and forecasts presented here.

168 **Table 1.** Epidemiological data and parameter values used in the model.

Parameter	Definition (units)	Value or [range]	Reference/source
μ_o	Intrinsic rate of infectivity of COVID-19 (day^{-1}) Calculated from confirmed COVID-19 cases during the first stage of the pandemic at Madrid, Spain (Ministy of Health, Spain): (https://www.mscbs.gob.es)	0.36	Calculated
δ	Relative demographic density (normalized respect to the demographic density of Madrid, Spain) (dimensionless) Parameter provided by model user to simulate a scenario	[0.75-2.00]	User defined
σ	Social distancing (dimensionless) Parameter provided by model user to simulate a scenario	[0-1]	User defined
$(1-\sigma)$	Fractional reduction in activity in the city due to social distancing [range:0-1]	[0-1]	Calculated from σ
P_o	Total population of the city (hab) Provided by model user from actual census data; (i.e.; www.citymayors.com)	[3,500,000-]	[14]
delay_q	Average number of days between infection and positive diagnostics and quarantine (days)	5	assumed
delay_r	Average number of days between infection and effective recovery or dead (days)	21	[15], [16].
a	Fraction of asymptomatic subjects among infected. Infered from serological study conducted in NYC: (www.cnn.com)	0.90	[11]
$(1-a)$	Fraction of symptomatic subjects among infected	0.10	[11]
m	Mortality rate expressed as a fraction of symptomatic individuals. Continuously updated by Johns Hopkins University (Coronavirus Research Center). https://coronavirus.jhu.edu/	0.069	*(2)*

In addition, the average time of sickness was set at 21 days in our simulations, as this is

within the reported range of 14 to 32 days[15], with a median time to recovery of 21

days[16]. Viral shedding can last for three to four weeks after the onset of symptoms, with

a peak at day 10-11.[17] Therefore, we assume that all those infected not quarantined

could continue to transmit the virus until full recovery (21 days). Similarly, asymptomatic

patients are only removed from the pool of susceptible persons after full virus clearance.

Note that, in the current version of our model, asymptomatic patients are considered part of

the population capable of transmitting COVID-19; reported evidence that suggests that

asymptomatic subjects (or minimally symptomatic patients) may exhibit similar viral

loads[18] to those of symptomatic patients and may be active transmitters of the

disease[19,20].

The average fraction of deceased patients worldwide is estimated as 0.064 of those infected

21 days before. This mortality percentage (case fatality rate) lies within the range reported

in the recent COVID-19 literature[21–24]. The time lapse of 14 days between the onset of

disease and death was statistically estimated by Linton et al. in a recent report [25]. We also

consider that the average time for bed occupancy of hospitalized patients is 14 days. The

estimated average hospitalization stays range from 9.3 to 13 days in the United States [26]

and China[27,28], but much longer stays have been reported in intensive care units in Italy

(20 to 25 days)[29]. Anecdotal data collected in México suggests that hospitalization stays

of at least two weeks are a more accurate figure for Latin American societies.

Definition of representative scenarios

We aimed to reproduce representative settings for COVID-19 progression; therefore, we

selected two hypothetical but realistic urban scenarios. Figure 1B shows the most densely

populated cities in the world (according to information concentrated in

www.citymayors.com)[14] represented by dots in a bidimensional plot of demographic

density versus population. Two clusters of cities can be readily identified. The first group of

5 to7 important cities in the world (i.e, Porto Alegre, Ankara, Athens, Guadalajara,

Monterrey, Barcelona) have populations between 3.0 and 3.7 million inhabitants and a

demographic density of ~5,000 inhabitants per square kilometer (hab km^2). A second group

is centered on the coordinates of a population of 10 million citizens and a demographic

density of 10,000 hab km^2 (i.e., Baghdad, Ho Chi Minh, Bangalore, Tianjin, Kinshasa,

Hyderabad). Based on this analysis, we centered our estimates of COVID-19 progression in

these two classes of "representative" cities (3.5 million inhabitants, 5,000 hab km^2; and 10

million citizens, 10,000 hab km^2).

We also based our estimates of μ_o, the intrinsic rate of COVID_19 propagation, on data

extracted from the local dynamics of the pandemics in Madrid (a city in our first category)

and New York City (a city in our second category). These two cities also belong to a

limited number of cities that have generated reliable datasets on the local progression of the

number of COVID-19 positive cases over time. We calculated the value of μ_o (*i.e.*, the

intrinsic rate of infectivity of SARS-CoV2 before interventions) by assuming that the initial

rate of propagation is $d(X)/dt = \mu_o [X]$, where $[X]$ is the number of initially infected

subjects. We then simply calculate the intrinsic rate of infection from the initial slope of a

plot of ln $[X]$ *vs* time, which is a usual procedure for calculation of intrinsic growth rates in

cell culture scenarios under the assumption of first order rate growth dependence.

Following this rationale, we set μ_o for all our simulations. Consistently, we noted that the

initial rate of propagation observed in NYC, a city with twice the demographic density of

Madrid, doubles this μ_o value. Therefore, we take the demographic density of Madrid as a

reference (5,185 hab km^2) and assume that multiplying μ_o by the normalized demographic

density (with respect to that in Madrid) is a reasonable procedure for adapting the model to

any urban area.

Figure 1. Model formulation and scenarios. (A) Schematic representation of the model. (B) Population and demographic density of the world largest cities.Two clusters of cities, referred here as Type I (green cluster) and Type II (red cluster) are indicated in a plot of population versus demographic density. The 51 largest cities in the world, according to www.citymayors.com/, are included[14]. Madrid Spain is indicated in yellow (•), New York City in red (•), and Mexico City in

228 green (•). (b) Natural log of the number of symptomatic versus time in Madrid from March 2 to

229 March 17 (initial stage of the pandemics in Spain). The initial rate of infection (μ_o) can be

230 calculated from the slope of this straight line.

Effect of social distancing and massive testing

Social distancing has been regarded as the one of the most effective buffering measures for

containment of local COVID-19 epidemics[30–33]. However, the effectiveness of massive

testing, either alone or in combination with social distancing, has been evaluated formally

in a limited number of contributions[34–36].

First, we conducted simulations in which we evaluated the independent impact of different

degrees of social distancing and massive testing in a Type I city (3.5 million inhabitants and

medium demographic density). Figure 2A shows the impact of different degrees of social

distancing at a fixed and basal value of massive testing. In this simulation, a basal value of

social distancing ($\alpha=0.1$) means that only 10% of the infected patients are diagnosed and

quarantined, while the rest of the infected subjects continue active until recovery. This

strategy is consistent with that adopted by countries that diagnosed essentially only those

subjects who were symptomatic and asked for medical assistance (i.e., México, Chile, and

Bolivia, with fewer than 2 tests per confirmed case [6]). The pandemic progression

(number of cumulative symptomatic cases, new infections per day, and bed occupancy per

day) is indicated with grey curves for a reference scenario with no social distancing and

basal level of testing. Higher degrees of enforcement of social distancing (i.e., such that the

demographic density is effectively reduced by 20, 40, and 60%) are presented with blue,

green, and red lines, respectively. Levels of social distancing of 20% and 40% delay the

pandemic curve by 15 and 30 days, whereas the pandemic progression is successfully

buffered only when social distancing effectively reduces demographic density (and

therefore activity) by 60% for extended times (i.e., for 6 months). Although eventually

effective, this strategy of drastic and prolonged social distancing may be unsustainable or

drastically damaging for the economy of low and medium income societies[32].

Figure 2B presents predictions for scenarios where no social distancing is implemented, but

where the level of diagnostic testing is increased from a basal value (10% of infected are

diagnosed and quarantined) to situations were 20, 30, and 40% of infected patients

(symptomatic and asymptomatic) are diagnosed within the first 3 days of viral shedding

and quarantined. These levels of massive testing, in the absence of social distancing

enforcement, are not sufficiently effective to buffer the pandemic.

Figure 2C shows a scenario in which social distancing is set at 20% and different testing

emphasis is applied. As before, trends related to the reference scenario of low testing and

no social distance enforcement are indicated in grey. The combination of moderate social

distancing and testing renders better results than any one of the two strategies

independently applied. When social distancing is elevated to a 40% and combined with

more intensive testing efforts, the epidemic peak is dramatically delayed. A value of 40%

social distancing in combination with an effort to identify and quarantine 30% of newly

infected subjects delays the peak of maximum bed occupancy from day 25 to day 75 and

lowers the highest demand of beds from 75,000 to fewer than 30,000. Increased testing at

40% social distancing further contributes to extinguish the epidemic peak.

273
274
275

Figure 3. Pandemic progression scenarios for a Type I city (3.5×10^6 citizens) with a medium demographic density (5,500 inhabitants km^{-2}). The number of new infections per day (thin and light line curves), the bed occupancy (thick line curves) and the cumulative number of infections (thin cumulative curve) are presented for each scenario. (a) Scenario I: basal level of testing (α=0.1) and increasingly higher levels of social distancing: σ=0.0 (gray), σ=0.2 (blue), σ=0.4 (green), and σ=0.6 (red). (b) Scenario II: social distance not enforced (σ=0.0) and increasing values of testing α=0.1 (gray), α=0.2 (blue), α=0.3 (green), and α=0.4 (red). (c) Scenario III: social distance modestly enforced (σ=0.2), and increasing values of testing, α=0.1 (blue), α=0.2 (green), and α=0.3 (red). (d) Scenario IV: social distance moderately enforced (σ=0.4) and increasing values of testing α=0.2 (blue), α=0.3 (green), and α=0.4 (red). Gray curves correspond to the pandemic progression with minimum intervention (no social distancing and α=0.1).

We also estimated the pandemic progression under the same set of scenarios for a densely

populated city (Type II: 5×10^6 citizens and 10,000 hab km^2). The results similarly indicate

that only a combined strategy of social distancing and scaled-up testing and quarantine may

effectively control the pandemic progression due to "selective social distancing". However,

the higher population leads to increases in the number of cases in the same time frame (let

us say, the first 120 days from pandemic onset) and in the maximum threshold of

symptomatic cases. The higher demographic density also causes a higher rate of transition.

Therefore, the containment strategies need to be stronger than those required for Type I

cities. For example, in the absence of intensified testing, the degree of social distancing

required to buffer the pandemic is much higher in a Type II city (α=0.75) than in a type I

city (α=0.60). Similarly, only aggressive social distancing interventions combined with

intensified testing, *i.e.*, (σ=0.6, α=0.3) or (σ=0.7, α=0.5) can mitigate the pandemic

progression in larger or denser cities (Type II). A summary of the results for different

combinations of scenarios is presented in Tables 2 and 3.

We present scenarios for both moderately and densely populated cities (Type I and II). Four

different indicators are calculated for each scenario, including the day of the epidemic peak,

the number of new infection cases at the epidemic peak, the cumulative number of

symptomatic infections after 120 days of the local pandemic onset (4 months), and the

maximum bed occupancy.

Figure 3. Pandemic progression scenarios for a Type II city (5.0×10^6 citizens) with a high demographic density (10,000 inhabitants km^{-2}). The number of new infections per day (thin and ligth line curves), the bed occupancy (thick line curves) and the cumulative number of infections (thin cumulative curve) are presented for each scenario. (a) Scenario I: basal level of testing (α=0.1) and increasingly higher levels of social distancing: σ=0.00 (gray), σ=0.25 (blue), σ=0.50 (green), and σ=0.75 (red). (b) Scenario II: social distance not enforced (σ=0.0) and increasing values of testing α=0.1 (gray), α=0.3 (blue), α=0.5 (green), and α=0.7 (red). (c) Scenario III: social distance enforced (σ=0.6) and increasing values of testing: α=0.1 (blue), α=0.3 (green), and α=0.5 (red). (d) Scenario IV: social distance moderately enforced (σ=0.7) and increasing values of testing: α=0.1 (blue), α=0.3 (green), and α=0.5 (red). Gray curves correspond to the pandemic progression with minimum intervention (no social distancing and α=0.1).

Table 2. Effect of social distancing and testing in a city with a demographic density of 5,500 inhabitants/km^2 and a population of 3.5×10^6 persons).

σ:			α								
			0.10	0.20	0.30	0.40	0.50	0.60	0.70	0.80	0.90
	0.00	peak @ day:	38.00	39.00	42.00	45.00	50.00	56.00	64.00	70.00	100.00
		infected after 120 days:	349037.52	349072.31	349410.58	349731.45	349801.94	349008.93	323718.47	134600.03	5963.75
		peak of infection (hab/day)	29155.11	26837.36	24343.10	21633.49	18652.11	15311.81	11469.93	2849.59	90.84
		maximum bed occupancy:	43076.11	41297.81	39084.22	36297.24	32740.85	28128.49	20667.05	5774.46	190.73
	0.25	peak @ day:	51.00	54.00	59.00	64.00	65.00	70.00	81.00	90.00	90.00
		infected after 120 days:	349994.09	349980.90	349723.77	342776.43	274280.90	122542.87	24923.94	2614.45	248.17
		peak of infection (hab/day)	21114.08	19067.32	16862.56	14462.14	8280.49	2397.63	398.56	37.26	2.59
		maximum bed occupancy:	35889.86	33437.60	30474.06	25109.72	14935.49	4900.12	833.91	78.27	5.45
	0.5	peak @ day:	67.00	67.00	76.00	81.00	82.00	86.00	88.00		
		infected after 120 days:	175936.83	91893.77	38845.99	13861.23	4332.07	1227.77	341.99		
		peak of infection (hab/day)	3803.14	1649.97	632.51	215.77	64.49	17.03	4.18		
		maximum bed occupancy:	7523.66	3411.07	1325.73	452.39	135.43	35.79	8.78		
	0.6	peak @ day:	77.00	81.00	83.00	86.00					
		infected after 120 days:	18919.36	8432.49	3534.87	1408.84					
		peak of infection (hab/day)	298.44	129.46	52.56	20.02					
		maximum bed occupancy:	625.81	271.66	110.40	42.07					
	0.7	peak @ day:	88.00								
		infected after 120 days:	1147.06								
		peak of infection (hab/day)	16.38								
		maximum bed occupancy:	34.42								

(*) Conditions at which the progression can be controlled or extinguished are indicated in light and intense green, respectively.

Table 3. Effect of social distancing and testing in a city with a demographic density of 10,000 inhabitants/km^2 and a population of 5.0×10^6 persons).

			0.10	0.20	0.30	0.40	0.50	0.60	0.70	0.80	0.90
		peak @ day:	19.00	19.00	19.00	20.00	21.00	21.00	22.00	24.00	25.00
	0.00	infected after 120 days:	499989.80	499971.06	499917.90	499766.95	499336.94	498102.78	494503.52	483634.61	446996.48
		peak of infection (hab/day)	86423.60	82575.85	78404.48	73841.74	68794.07	63125.83	56629.06	48953.93	39422.43
		maximum bed occupancy:	73747.96	73345.63	72776.58	71953.49	70731.66	68861.46	65889.88	60938.49	52151.75
		peak @ day:	25.00	26.00	27.00	28.00	30.00	32.00	35.00	39.00	47.00
	0.25	infected after 120 days:	499846.93	499665.38	499268.89	498409.15	496596.85	493100.98	487611.16	479682.50	443985.07
		peak of infection (hab/day)	63930.77	60111.56	55971.34	51440.99	46422.90	40772.27	34255.89	26450.93	16419.13
		maximum bed occupancy:	70822.64	69733.12	68276.26	66293.98	63540.74	59619.71	53853.41	44986.81	30352.40
		peak @ day:	38.00	41.00	44.00	46.00	51.00	57.00	64.00	72.00	96.00
σ:	0.50	infected after 120 days:	498882.25	499096.74	499540.23	499809.64	499807.31	498253.90	446201.67	158799.47	6043.61
		peak of infection (hab/day)	41649.98	38338.88	34775.60	30904.68	26645.47	21873.49	15986.09	3184.80	92.64
		maximum bed occupancy:	61537.12	58996.65	55834.29	51852.80	46772.08	40182.73	27909.42	6544.93	194.56
		peak @ day:	49.00	52.00	56.00	61.00	64.00	67.00	80.00	90.00	90.00
	0.60	infected after 120 days:	499990.74	499988.72	499925.44	498000.70	455117.57	259517.01	62505.34	6072.10	390.58
		peak of infection (hab/day)	32518.26	29514.18	26280.30	22762.02	17097.07	6020.73	1047.72	91.03	4.37
		maximum bed occupancy:	53795.88	50486.51	46503.25	41012.07	29013.61	11822.72	2187.91	191.19	9.19
		peak @ day:	63.00	65.00	67.00	67.00	76.00	82.00	94.00		
	0.70	infected after 120 days:	486459.87	414489.06	263372.49	115959.71	36130.22	8585.78	1674.53		
		peak of infection (hab/day)	21722.22	13239.99	5938.16	2056.64	581.04	130.80	23.44		
		maximum bed occupancy:	35466.46	23463.24	11668.79	4276.82	1216.45	274.64	49.25		

(*) Conditions at which the progression can be controlled or extinguished are indicated in light and intense green, respectively

Next, we investigated the fidelity of the model prediction by simulating the advance of the

pandemic in Madrid, NYC, and Mexico City. The number of new infections per day in

these three cities has been made available by government officials [37–39]. Interestingly,

the demographic characteristics of these major cities exhibit important differences, as well

as the types of counter-measures adopted to contain COVID-19.

Madrid (a Type-I city) and NYC (nearly a Type-II city) have practically extinguished the

pandemic. Therefore, the position and magnitude of the pandemic peak offers valuable

information to estimate values of the magnitude of social distancing (σ) and diagnostic

effort (α). In contrast, Mexico City has not reached the pandemic peak yet, and struggles to

contain COVID-19 in a challenging demographic situation. We found sets of parameters

that properly describe the evolution of COVID-19 in each of these cities, despite the

obvious differences in the behavior of each progression curve (Figure 4). For Madrid, our

simulations suggest that social distancing measures have achieved a degree of 58% of

reduction in population density (α=0.58). However, even considering these relatively

higher values of social distancing, an aggressive testing program (α=0.50) was needed to

bend the curve at a cumulative number of ~70,000 cases and reduce the emergence of new

cases to the current levels (less than 10 per day). This implies that overall approximately

50% of the active infected subjects were found and quarantined through testing.

We also fitted the model to the pandemic progression observed in NYC. NYC is a densely

populated area with a population mark of 8,400,000 inhabitants (i.e., nearly a Type-II city).

Therefore, only a combination of social distancing and intensified testing can stop

progression effectively (Table 3). Our results suggest that NYC has applied a strategy

mostly based on aggressive testing.

Figure 4. Progression of the COVID-19 Pandemic in (a) Madrid, (b) New York City (NYC), and (c) Mexico City. Actual data points, as officially reported, are shown using circles. Model predictions of new COVID-19 cases (yellow line) and simulation predictions of the cumulative number of symptomatic patients (blue line). The values of α and σ used in the simulations for each city are indicated within the corresponding pannels.

Indeed, a scenario based on a sustained level of social distancing of 27% efficacy (σ=0.27;

effective reduction of 30% in demographic density) and a massive testing effort (α=0.98) is

the combination that better recapitulates the actual pandemic evolution in NYC. NYC is,

therefore, a remarkable example of the efficacy of massive diagnosis and quarantine, as a

city that was able to stop COVID-19 progression at a cumulative count of ~250,000

symptomatic subjects, which is about 25% of the maximum expected. In perspective, with

an effective distancing of 27% and no aggressive testing (i.e., α=0.50 instead of α=0.98),

the peak of bed occupancy in the city would have been at least three-fold higher, causing a

total collapse of the hospital system. Our results also show that demographic density is a

key factor in COVID-19 progression. Note that the testing effort in NYC was more intense

than in Madrid. However, NYC has double the demographic density of Madrid, resulting in

a higher number of those infected than in Madrid (250,000 versus 70,000).

While Madrid and NYC have transitioned through the pandemic peak and successfully

extinguished the pandemic, Mexico City is still struggling to contain the pandemics.

Several mathematical models have been used to forecast pandemic scenarios for Mexico

City [40–42]. However, accurately predicting the progression of COVID-19 and the

occurrence of the pandemic peak in the capital of Mexico has been challenging. Mexico

City has a demographic density of 1.69 times that of Madrid and a population of more than

15,000 within the city limits. In terms of demographic density, Mexico City lies between a

Type-I and Type-II city, possessing a demographic density 1.69 times greater than Madrid.

However, in terms of population, Mexico City is double that of NYC. The Mexico City

Metropolitan Area, which comprehends the city and its surrounding municipalities in

Estado de México, houses 25,000,000 inhabitants. From the scenarios simulated before

(Figure 4), we may readily infer that only a combination of aggressive social distancing and

massive testing effort can stop pandemic progression in Mexico City. Mexican public

health officials have publicly stated their decision to deemphasize diagnostics, instead

privileging social distancing in the entire Mexican territory. Figure 4C compares the actual

evolution of the number of cases in Mexico City versus the prediction of our model for a

scenario where social distancing is set at $\sigma=0.75$ (75% effective reduction on demographic

density) and the testing effort at $\alpha=0.10$% (only 10% of infected individuals are effectively

quarantined after being diagnosed). The Mexican strategy has been successful in delaying

the pandemic's progression, but not in bending the slope of the epidemic curve. As a result,

Mexico City is steadily positioned in a pandemic plateau, with a nearly constant number of

cases per day (600 cases), which is consistent with journalistic information and official data

(https://coronavirus.gob.mx/datos/)[38].

Concluding remarks

Here we introduce a mathematical model, based on demographic and clinical data that

enables evaluating the relative benefit of social distancing and massive testing. Using this

simple model, we investigate scenarios of COVID-19 evolution in two types of

representative cities (i.e., 3,500,000 inhabitants and 5,000 hab km^2, and 5.0 X 10^6

inhabitants and 10,000 hab km^2).

Our modeling simulations show that for Type-I cities, extreme and sustained social

distancing (i.e., effectively decreasing the demographic density by 60% or more) may

extinguish the pandemic progression. However, in Type-II cities (or larger), only

combinations of social distancing and aggressive testing can effectively control the

pandemic evolution. This finding has relevant implications for the planning of

countermeasures for the effective containment of pandemic progression and for the

design/redesign of urban areas. The concept of sustainability and cost-effectiveness of

densely populated urban areas has to be revisited. Our results make explicit that large cities

are highly vulnerable to epidemic crisis.

In principle, this model can be adapted to any urban area by setting the population and the

demographic density. The predictions on the evolution of COVID-19 based on this

mathematical model could represent important tools for designing and/or evaluating

countermeasures.

Acknowledgments

418 MMA and GTdS acknowledge the funding received from CONACyT (Consejo Nacional de

419 Ciencia y Tecnología, México) and Tecnológico de Monterrey.

Author contributions

422 MMA and GTdS collected and analyzed epidemiology data. MMA formulated the model

423 and ran the simulations. MMA and GTdS wrote the manuscript. Both authors reviewed and

424 approved the manuscript.

Competing interest

427 The authors declare no competing interests.

References

431   1.   Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First

432   Case of 2019 Novel Coronavirus in the United States. N Engl J Med. Massachusetts

433   Medical Society; 2020; doi:10.1056/nejmoa2001191

434   2.   Coronavirus Research Center. Johns Hopkins University. (2020)

435   https://coronavirus.jhu.edu/

436   3.   Cohen J, Kupferschmidt K. Countries test tactics in "war" against COVID-19.

437   Science. American Association for the Advancement of Science; 2020;367: 1287–

438   1288. doi:10.1126/science.367.6484.1287

439   4.   Salathé M, Althaus CL, Neher R, Stringhini S, Hodcroft E, Fellay J, et al. COVID-

440   19 epidemic in Switzerland: on the importance of testing, contact tracing and

441   isolation. Swiss Med Wkly. EMH Media; 2020;150: w20225.

442   doi:10.4414/smw.2020.20225

443   5.   Lee D, Lee J. Testing on the move: South Korea's rapid response to the COVID-19

444   pandemic. Transportation Research Interdisciplinary Perspectives. Elsevier Ltd;

445   2020. p. 100111. doi:10.1016/j.trip.2020.100111

446   6.   Our world in data. (2020) https://ourworldindata.org/coronavirus-testing.

447   7.   Terriau A, Albertini J, Poirier A, Le Bastard Q. Impact of virus testing on COVID-

448   19 case fatality rate: estimate using a fixed-effects model.

449   doi:10.1101/2020.04.26.20080531

450   8.   Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Reinfection could not occur in

451   SARS-CoV-2 infected rhesus macaques. bioRxiv. Cold Spring Harbor Laboratory;

452   2020; 2020.03.13.990226. doi:10.1101/2020.03.13.990226

9.   Prompetchara E, Ketloy C, Palaga T. Allergy and Immunology Immune responses in

COVID-19 and potential vaccines: Lessons learned from SARS and MERS

epidemic. doi:10.12932/AP-200220-0772

10.   Liu W, Fontanet A, Zhang P, Zhan L, Xin Z, Baril L, et al. Two￼Year Prospective

Study of the Humoral Immune Response of Patients with Severe Acute Respiratory

Syndrome. J Infect Dis. Oxford University Press (OUP); 2006;193: 792–795.

doi:10.1086/500469

11.   CNBC. "New York antibody study estimates 13.9% of residents have had the

coronavirus, Gov. Cuomo says". (2020) https://www.cnbc.com/2020/04/23/new-

york-antibody-study-estimates-13point9percent-of-residents-have-had-the-

coronavirus-cuomo-says.html

12.   Elizondo-Montemayor L, Alvarez MM, Hernández-Torre M, Ugalde-Casas PA,

Lam-Franco L, Bustamante-Careaga H, et al. Seroprevalence of antibodies to

influenza A/H1N1/2009 among transmission risk groups after the second wave in

Mexico, by a virus-free ELISA method. Int J Infect Dis. Elsevier; 2011;15: e781–

e786. doi:10.1016/j.ijid.2011.07.002

13.   Zimmer SM, Crevar CJ, Carter DM, Stark JH, Giles BM, Zimmerman RK, et al.

Seroprevalence Following the Second Wave of Pandemic 2009 H1N1 Influenza in

Pittsburgh, PA, USA. doi:10.1371/journal.pone.0011601

14.   City Mayors. "Largest cities in the world by population". (2020)

http//: www.citymayors.com

15.   Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR Test Results in

Patients Recovered From COVID-19. JAMA. 2020; doi:10.1001/jama.2020.2783

16.   Bi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and Transmission of

COVID-19 in Shenzhen China: Analysis of 391 cases and 1,286 of their close

contacts. medRxiv. Cold Spring Harbor Laboratory Press; 2020;

2020.03.03.20028423. doi:10.1101/2020.03.03.20028423

17.   Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, et al.

Virological assessment of hospitalized patients with COVID-2019. Nature. Nature

Research; 2020;581: 465–469. doi:10.1038/s41586-020-2196-x

18.   Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral

Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med.

Massachusetts Medical Society; 2020;382: 1177–1179. doi:10.1056/NEJMc2001737

19.   Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed Asymptomatic

Carrier Transmission of COVID-19. JAMA. 2020; doi:10.1001/jama.2020.2565

20.   MacIntyre CR. Global spread of COVID-19 and pandemic potential. Glob

Biosecurity. University of New South Wales; 2020;1. doi:10.31646/gbio.55

21.   Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome

coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The

epidemic and the challenges. International Journal of Antimicrobial Agents. Elsevier

B.V.; 2020. p. 105924. doi:10.1016/j.ijantimicag.2020.105924

22.   Jung S, Akhmetzhanov AR, Hayashi K, Linton NM, Yang Y, Yuan B, et al. Real-

Time Estimation of the Risk of Death from Novel Coronavirus (COVID-19)

Infection: Inference Using Exported Cases. J Clin Med. Multidisciplinary Digital

Publishing Institute; 2020;9: 523. doi:10.3390/jcm9020523

23.   Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of

COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med.

Lancet Publishing Group; 2020;0. doi:10.1016/S2213-2600(20)30076-X

24.   Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in Case Fatality

502   Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries.

503   2020;14: 125–128. doi:10.3855/jidc.12600

504   25.   Linton NM, Kobayashi T, Yang Y, Hayashi K, Akhmetzhanov AR, Jung S-M, et al.

505   Epidemiological characteristics of novel coronavirus infection: A statistical analysis

506   of publicly available case data. doi:10.1101/2020.01.26.20018754

507   26.   Lewnard JA, Liu VX, Jackson ML, Schmidt MA, Jewell BL, Flores JP, et al.

508   Incidence, clinical outcomes, and transmission dynamics of severe coronavirus

509   disease 2019 in California and Washington: Prospective cohort study. BMJ. BMJ

510   Publishing Group; 2020;369. doi:10.1136/bmj.m1923

511   27.   Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of

512   Coronavirus Disease 2019 in China. N Engl J Med. Massachussetts Medical Society;

513   2020;382: 1708–1720. doi:10.1056/NEJMoa2002032

514   28.   Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of

515   COVID-19 patients with digestive symptoms in Hubei, China: A descriptive, cross-

516   sectional, multicenter study. Am J Gastroenterol. Wolters Kluwer Health; 2020;115:

517   766–773. doi:10.14309/ajg.0000000000000620

518   29.   Rosenbaum L. Facing Covid-19 in Italy - Ethics, Logistics, and Therapeutics on the

519   Epidemic's Front Line. N Engl J Med. NLM (Medline); 2020;382: 1873–1875.

520   doi:10.1056/NEJMp2005492

521   30.   Anderson RM, Heesterbeek H, Klinkenberg D, Hollingsworth TD. How will

522   country-based mitigation measures influence the course of the COVID-19 epidemic?

523   The Lancet. Lancet Publishing Group; 2020. pp. 931–934. doi:10.1016/S0140-

524   6736(20)30567-5

31.   Isolation, quarantine, social distancing and community containment: pivotal role for

old-style public health measures in the novel coronavirus (2019-nCoV) outbreak |

Journal of Travel Medicine | Oxford Academic [Internet]. [cited 24 Mar 2020].

Available: https://academic.oup.com/jtm/article/27/2/taaa020/5735321

32.   Walker PGT, Whittaker C, Watson OJ, Baguelin M, Winskill P, Hamlet A, et al. The

impact of COVID-19 and strategies for mitigation and suppression in low- and

middle-income countries. Science (80-). American Association for the

Advancement of Science (AAAS); 2020; eabc0035. doi:10.1126/science.abc0035

33.   Kissler SM, Tedijanto C, Goldstein E, Grad YH, Lipsitch M. Projecting the

transmission dynamics of SARS-CoV-2 through the postpandemic period. Science.

NLM (Medline); 2020;368: 860–868. doi:10.1126/science.abb5793

34.   Giordano G, Blanchini F, Bruno R, Colaneri P, Di Filippo A, Di Matteo A, et al.

Modelling the COVID-19 epidemic and implementation of population-wide

interventions in Italy. Nat Med. Nature Research; 2020;26: 855–860.

doi:10.1038/s41591-020-0883-7

35.   Optimal Covid-19 Quarantine and Testing Policies by Facundo Piguillem, LIYAN

SHI⬚:: SSRN [Internet]. [cited 17 Jul 2020]. Available:

https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3594243

36.   Barak B, Nitzan M, Tannenbaum NR, Yuval J. Optimizing testing policies for

detecting COVID-19 outbreaks. 2020; Available: http://arxiv.org/abs/2007.04827

37.   Ministerio de Sanidad, Consumo y Bienestar Social, Españña. (Ministry of Helath,

Spain). 2020.

https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-

China/situacionActual.htm

38.   New York City Government. Health. COVID-19 Data. 2020.

550   https://www1.nyc.gov/site/doh/covid/covid-19-data.page

551   39.   CONACyT. COVID-19 México. Tablero México. (2020)

552   https://coronavirus.gob.mx/datos/

553   40.   Mena RH, Velasco-Hernandez JX, Mantilla-Beniers NB, Carranco-Sapiéns GA,

554   Benet L, Boyer D, et al. Using posterior predictive distributions to analyse epidemic

555   models: COVID-19 in Mexico City. 2020; Available:

556   http://arxiv.org/abs/2005.02294

557   41.   Avila-Ponce de León U, Pérez ÁGC, Avila-Vales E. An SEIARD epidemic model

558   for COVID-19 in Mexico: mathematical analysis and state-level forecast. medRxiv.

559   Cold Spring Harbor Laboratory Press; 2020; 2020.05.11.20098517.

560   doi:10.1101/2020.05.11.20098517

561   42.   Alvarez MM, Gonzalez-Gonzalez E, Santiago GT. Modeling COVID-19 epidemics

562   in an Excel spreadsheet: Democratizing the access to first-hand accurate predictions

563   of epidemic outbreaks. medRxiv. Cold Spring Harbor Laboratory Press; 2020;

564   2020.03.23.20041590. doi:10.1101/2020.03.23.20041590

Supporting Information

567   **S1 File.** Excel file that contains mathematical modelling formulation in Excel

A

Social distancing

$$\frac{dX}{dt} = \mu_o\,\delta\,(1-\sigma)\,\mathbf{(X-R)}\,(P_o-X)/P_o$$

σ

0.0   1.0

Infective Subjects (X) — Retrieved Subjects (R)

Asymptomatic infected (A)   Symptomatic infected (S)

Diagnosed & Quarantined   Recovered or deceased

Testing effort

α

0.0   1.0

Cumulative infected population   Po-X

Total Population (P_o)

B

Demographic density (hab km²)

Population (hab)

ln (symptomatic)

Time (days)

$\mu_o=0.36$
$r^2=0.97$